Studies have shown high MIR155HG expression levels in lymphomas 15-17, leukemia 18, gliomas 19-21, and non-small-cell lung cancer 22, and MIR155HG functions as an oncogene in these cancers. This evidence concerns the gene MIR155HG and non-small cell lung carcinoma.